{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:34:42Z","timestamp":1789058082995,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":813,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL143050"],"award-info":[{"award-number":["HL143050"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA 0008748"],"award-info":[{"award-number":["P30CA 0008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["16672"],"award-info":[{"award-number":["16672"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtct.2020.10.003","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T21:53:01Z","timestamp":1616104381000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients"],"prefix":"10.1016","volume":"27","author":[{"given":"Sanjeet S.","family":"Dadwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias M.","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genofeva","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2020.10.003_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2020.10.003_bib0004","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10096-019-03794-7","article-title":"Levels of evidence supporting clinical practice guidelines on invasive aspergillosis","volume":"39","author":"Tejada","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study","volume":"95","author":"Cordonnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2020.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.bbmt.2014.04.016","article-title":"Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis","volume":"20","author":"Liu","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.003_bib0007","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.12421","article-title":"Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation","volume":"94","author":"Dadwal","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s15010-008-8129-5","article-title":"Occupation, lifestyle, diet, and invasive fungal infections","volume":"36","author":"Sipsas","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.jtct.2020.10.003_bib0009","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz037","article-title":"Infectious complications after umbilical cord blood transplantation for hematological malignancy","volume":"6","author":"Linder","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bmt.2013.132","article-title":"The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT","volume":"49","author":"Marek","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.003_bib0012","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2003-01-0267","article-title":"Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study","volume":"102","author":"Marty","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0013","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation","volume":"359","author":"Bochud","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0014","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2016-10-743294","article-title":"Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation","volume":"129","author":"Fisher","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0015","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41467-018-04912-3","article-title":"Genetic deficiency of NOD2 confers resistance to invasive aspergillosis","volume":"9","author":"Gresnigt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2020.10.003_bib0016","article-title":"Outcomes in invasive pulmonary aspergillosis infections complicated by respiratory viral infections in patients with hematologic malignancies: a case-control study","volume":"6","author":"Magira","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0017","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0018","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/imj.12601","article-title":"Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014","volume":"44","author":"Chang","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtct.2020.10.003_bib0019","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.003_bib0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0021","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0022","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0023","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0024","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0025","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0026","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2020.10.003_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/myc.12924","article-title":"Isavuconazole to prevent invasive fungal infection in immunocompromised adults: initial experience at an academic medical centre","volume":"62","author":"Bowen","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.jtct.2020.10.003_bib0029","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0030","article-title":"Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase II study [e-pub ahead of print]","author":"Bose","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020005884","article-title":"How I transplant a patient with a history of invasive fungal disease [e-pub ahead of print]","author":"Puerta-Alcalde","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0032","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.003_bib0033","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/civ297","article-title":"Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation","volume":"61","author":"Kanamori","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0034","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/myc.12167","article-title":"Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers","volume":"57","author":"Ariza-Heredia","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.jtct.2020.10.003_bib0036","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0091-6749(88)90917-7","article-title":"Woodman's disease: hypersensitivity pneumonitis from cutting live trees","volume":"81","author":"Dykewicz","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0037","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/a907102d","article-title":"Organic dust and gaseous contaminants at woodworking shops","volume":"2","author":"Abdel Hameed","year":"2000","journal-title":"J Environ Monit"},{"issue":"suppl_2","key":"10.1016\/j.jtct.2020.10.003_bib0038","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/mmy\/myy090","article-title":"The role of occupational Aspergillus exposure in the development of diseases","volume":"57","author":"Sabino","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0039","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/bmt.2009.203","article-title":"Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation","volume":"45","author":"Shannon","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.003_bib0041","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1002\/cncr.25905","article-title":"Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study","volume":"117","author":"Sampsonas","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2020.10.003_bib0042","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-991520","article-title":"Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure","volume":"28","author":"Baughman","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00962-18","article-title":"Bronchoalveolar lavage fluid cytology in culture-documented invasive pulmonary aspergillosis in patients with hematologic diseases: analysis of 67 episodes","volume":"56","author":"Fern\u00e1ndez-Cruz","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0044","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0045","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/JCM.06423-11","article-title":"Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity","volume":"50","author":"D'Haese","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0046","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis","volume":"59","author":"Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0047","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0048","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jinf.2014.04.008","article-title":"The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections","volume":"69","author":"Rose","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2020.10.003_bib0049","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/JCM.00285-14","article-title":"Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States","volume":"52","author":"Vergidis","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0050","unstructured":"Karius. Available at: https:\/\/kariusdx.com\/pathogenlist\/3.6. Accessed January 21, 2020."},{"key":"10.1016\/j.jtct.2020.10.003_bib0051","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1469-0691.2010.03323.x","article-title":"Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species","volume":"17","author":"Alanio","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtct.2020.10.003_bib0052","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/JCM.01862-06","article-title":"Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens","volume":"45","author":"Lau","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0053","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/mmy\/myv092","article-title":"Clinical utility of panfungal polymerase chain reaction for the diagnosis of invasive fungal disease: a single center experience","volume":"54","author":"Trubiano","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0054","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0056","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0057","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0058","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0059","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jtct.2020.10.003_bib0060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0062","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2020.10.003_bib0063","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0064","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/ciu581","article-title":"Antifungal combination therapy for invasive aspergillosis","volume":"59","author":"Marti\u00edn-Pe\u00f1a","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"suppl 2)","key":"10.1016\/j.jtct.2020.10.003_bib0066","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2001.tb00010.x","article-title":"Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients","volume":"7","author":"Caillot","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtct.2020.10.003_bib0067","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jinf.2013.12.008","article-title":"Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome","volume":"68","author":"Gamaletsou","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2020.10.003_bib0068","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.leu.2400811","article-title":"Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study","volume":"11","author":"Dignani","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2020.10.003_bib0069","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.10.003_bib0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/jcm9020610","article-title":"A mortality prediction rule for hematology patients with invasive aspergillosis based on serum galactomannan kinetics","volume":"9","author":"Mercier","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2020.10.003_bib0071","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciz1195","article-title":"How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions","volume":"71","author":"Fern\u00e1ndez-Cruz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0072","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0073","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06795.x","article-title":"The impact of azole resistance on aspergillosis guidelines","volume":"1272","author":"Georgiadou","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtct.2020.10.003_bib0074","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0075","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0076","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0077","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01435-19","article-title":"Using state transition models to explore how the prevalence of subtherapeutic posaconazole exposures impacts the clinical utility of therapeutic drug monitoring for posaconazole tablets and oral suspension","volume":"63","author":"Lewis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0078","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0079","doi-asserted-by":"crossref","first-page":"e27564","DOI":"10.1002\/pbc.27564","article-title":"Epidemiology of invasive fungal infections in immunocompromised children: an Australian national 10-year review","volume":"66","author":"Bartlett","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.003_bib0080","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children","volume":"6","author":"Pana","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.003_bib0081","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/jpids\/pix053","article-title":"Recognition and clinical presentation of invasive fungal disease in neonates and children","volume":"6","author":"King","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.jtct.2020.10.003_bib0082","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00247-003-0919-4","article-title":"The radiological spectrum of invasive aspergillosis in children: a 10-year review","volume":"33","author":"Thomas","year":"2003","journal-title":"Pediatr Radiol"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.003_bib0083","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/jpids\/pix055","article-title":"Diagnostic imaging and invasive fungal diseases in children","volume":"6","author":"Katragkou","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jtct.2020.10.003_bib0084","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtct.2020.10.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01783-19","article-title":"A case-series and literature review of Isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0086","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0087","series-title":"Newer Antifungal Agents in Pediatrics","author":"Steinbach","year":"2019"},{"key":"10.1016\/j.jtct.2020.10.003_bib0088","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2020.10.003_bib0089","unstructured":"US Food and Drug Administration. KYMRIAH (tisagenlecleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Accessed January 18, 2020."},{"key":"10.1016\/j.jtct.2020.10.003_bib0090","unstructured":"US Food and Drug Administration. YESCARTA (axicabtagene ciloleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel. Accessed January 18, 2020 2020."},{"key":"10.1016\/j.jtct.2020.10.003_bib0091","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.003_bib0092","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2020.10.003_bib0093","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/cid\/ciaa031","article-title":"Chimeric antigen receptor T-cell immunotherapy and need for prophylaxis for invasive mold infections","volume":"71","author":"Lewis","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:26Z","timestamp":1763002886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636720300026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2666636720300026"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2020.10.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}